DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Tauroursodeoxycholic acid is an investigational drug.
There have been 21 clinical trials for Tauroursodeoxycholic acid. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2012.
The most common disease conditions in clinical trials are Sclerosis, Amyloidosis, and Motor Neuron Disease. The leading clinical trial sponsors are Washington University School of Medicine, Beijing Trendful Kangjian Medical Information Consulting Limited Company, and IRCCS Policlinico S. Matteo.
There are two hundred and seventy-three US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Tauroursodeoxycholic acid
|Targeting ER Stress in Vascular Dysfunction||Colorado State University||Early Phase 1|
|TUDCA as a Therapy for Ulcerative Colitis (UC)||Crohn's and Colitis Foundation||Phase 1|
|TUDCA as a Therapy for Ulcerative Colitis (UC)||Washington University School of Medicine||Phase 1|
Top disease conditions for Tauroursodeoxycholic acid
Top clinical trial sponsors for Tauroursodeoxycholic acid
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tauroursodeoxycholic acid||Start Trial||Measurement method for human pancreatic lipase activity||ASAHI KASEI PHARMA CORPORATION (Tokyo, JP)||Start Trial|
|Tauroursodeoxycholic acid||Start Trial||17-hydroxyprogesterone ester-containing oral compositions and related methods||Lipocine Inc. (Salt Lake City, UT)||Start Trial|
|Tauroursodeoxycholic acid||Start Trial||Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use||Vivus, Inc. (Campbell, CA)||Start Trial|
|Tauroursodeoxycholic acid||Start Trial||Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics||The Regents of the University of California (Oakland, CA)||Start Trial|
|Tauroursodeoxycholic acid||Start Trial||Methods and systems for determining autism spectrum disorder risk||Laboratory Corporation of America Holdings (Burlington, NC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Tauroursodeoxycholic acid||China||105164273||2033-04-18||Start Trial|
|Tauroursodeoxycholic acid||European Patent Office||2987867||2033-04-18||Start Trial|
|Tauroursodeoxycholic acid||Spain||2654437||2033-04-18||Start Trial|
|Tauroursodeoxycholic acid||Japan||6064041||2033-04-18||Start Trial|
|Tauroursodeoxycholic acid||Japan||WO2014171505||2033-04-18||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|